Literature DB >> 8471337

Economic evaluation and quality of life assessments in cancer clinical trials: the CHART Trial.

J Morris1, M Goddard.   

Abstract

Arguments are being made more frequently to incorporate economic evaluations and quality of life assessments into clinical trials. Using a randomised, multicentre, phase 3 cancer clinical trial as an example, this paper outlines the importance of including such assessments; the practical considerations associated with the design of such trials; the methods for collecting such data; and, how such data can be used. Finally, it is emphasised that the anticipated benefits of collecting data relating to resource use and quality of life should outweigh the associated costs to research funding organisations.

Entities:  

Mesh:

Year:  1993        PMID: 8471337     DOI: 10.1016/s0959-8049(05)80364-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

Review 1.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.

Authors:  J Mauskopf; K Schulman; L Bell; H Glick
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

3.  The use of quality of life data in clinical practice.

Authors:  J Morris; D Perez; B McNoe
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

4.  Quality of life bibliography and indexes: 1993 update.

Authors:  R A Berzon; G P Simeon; R L Simpson; M A Donnelly; H H Tilson
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

5.  Health economics and quality of life in cancer trials: report based on a UKCCCR workshop. United Kingdom Coordinating Committee on Cancer Research.

Authors:  R Fitzpatrick; L Davies
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.